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Wereport thecaseofa 37-year-old womanwho hada relapse ofacute myeloidleukemia(AML) during treatment forchronicgraft
versus host disease (cGVHD) after allogeneic bone marrow transplantation. She was originally suspected of having autoimmune
pancreatitis. Relapse of AML often occurs at extramedullary sites. Whereas the pancreas is rare as an organ of AML relapse,
physicians should be aware that enlargement of the pancreas could be a sign of relapsed AML when excluding autoimmune
pancreatitis, particularly during active cGVHD after allogeneic stem cell transplantation.
1.Introduction
Relapses of acute leukemia is devastating event after allo-
geneic hematopoietic stem cell transplantation. Some of
them occur at extramedullary sites [1–3]. Diﬀuse inﬁltration
of leukemia cells mimics inﬂammation of the organs.
Chronic graft versus host disease (cGVHD) cause inﬂamma-
tion of organs and frequently resemble autoimmune diseases
[4]. We report the case of extramedullary relapse of acute
myeloid leukemia with t(16;21)(p11;q22) during treatment
for cGVHD. This case was originally suspected of having
autoimmune pancreatitis due to characteristic symptoms
and radiologic ﬁndings of AIP.
2.CaseReport
A 37-year-old woman was referred to Tsukuba University
Hospital because of fever and pancytopenia in February
2003. The ﬁndings of a bone marrow aspiration and biopsy
established a diagnosis of acute myeloid leukemia (AML)
with maturation. Cytogenetic analysis of the leukemia cells
revealed complex abnormalities involving t(16;21)(p11;q22)
translocation. A FUS/TLS-ERG fusion transcript was
detected by RT-PCR. The patient received cytarabine and
daunorubicin induction chemotherapy and achieved com-
plete remission after2 courses oftherapy. An allogeneic bone
marrow transplantation (BMT) using bone marrow from
an unrelated donor was performed at the ﬁrst remission in
October 2003. The conditioning regimen was Cyclophos-
phamide (60mg/kg/day, day −6a n dd a y−5) and total body
irradiation (12Gy/6fr, day −4t od a y−2). The FUS/TLS-
ERG fusion transcript was undetectable after the BMT.
Two years and eight months after the BMT, the patient
experienced progressive appetite loss and underwent a gas-
trointestinal ﬁberscopic examination. A biopsy of the gastric
mucosarevealedinﬁltration ofleukemiacells.Thebonemar-
row examination showed normal cellularity with increased
blasts, and a diagnosis of relapsed AML was made in June
2006. She achieved a second remission after undergoing
idarubicin and cytarabine reinduction therapy. A second
unrelated BMT was performed in April 2007 from a donor
diﬀerent from the donor in the ﬁrst BMT. The conditioning2 ISRN Hematology
regimen was intravenous Busulfan (3.2mg/kg/day, day −7
to −4), Cyclophosphamide (60mg/kg/day, day −3), and
antithymocyte globulin (15mg/kg/day, day −2a n dd a y−1).
While the patient was suﬀering from cGVHD involving
the skin and oral cavity, fever, epigastric pain, and diar-
rhea developed in July 2008. A mass was palpable in the
upper abdomen. Serum amylase, aspartate aminotransferase
(AST), alanine aminotransferase (ALT), and bilirubin levels
were 327IU/L, 1575IU/L, 855IU/L, and 1.6mg/dL, respec-
tively. No signs of relapse were noted in the bone marrow
aspirate. A CT scan revealed diﬀuse swelling of the pancreas
(Figure 1(a)). Amagnetic resonance cholangiopancreatogra-
phy (MRCP) revealed diﬀuse narrowing of the main pan-
creatic duct (Figure 1(b)), a ﬁnding consistent with autoim-
mune pancreatitis. A tentative diagnosis of pancreatitis
associated with chronic GVHD was made. Administration
of 1mg/kg prednisolone and 1500mg gabexate mesilate was
started. Her symptoms improved and the serum amylase
level returned to the normal range. The pancreas diminished
in size, yet was still larger than normal (Figure 1(c)). Three
months later, epigastralgia, jaundice, and elevated serum
amylase ﬂared up again. Blasts appeared in the peripheral
blood and the bone marrow. A ﬁber gastroscopic study
revealed an irregular thickening of the gastric mucosa, and
a biopsy demonstrated an inﬁltration ofleukemiccells. A CT
scan detected multiple tumors in the anterior mediastinum,
right atrium, stomach, and pancreatic head. Administration
ofgemtuzumab ozogamicin was temporarily eﬀective for the
epigastric pain. The patient chose palliative care and died of
AML in June 2009.
3.Discussion
Pancreatitis has been reported in conjunction with acute
GVHD [5, 6], but not with chronic GVHD. Chronic GVHD
frequentlyresemblesautoimmunediseases[4].Autoimmune
pancreatitis (AIP) is a well-recognized entity [7]. Character-
istic radiologic ﬁndings of AIP made us administer steroids
in the context of chronic GVHD. However, the serum level
of IgG4, which is often elevated in autoimmune pancreatitis,
was normal, and the pancreatitis recurred during the steroid
maintenance therapy. Furthermore, a biopsy of the gastric
mucosa, which was one of multiple tumors detected by the
CT scan, demonstrated an inﬁltration of leukemic cells. We
were not able to perform a histological study of the pancreas,
but we eventually concluded that the pancreatitis was due
to inﬁltration of leukemia cells rather than chronic GVHD-
associated pancreatitis.
Aroundaquartertoahalfofpatientswithacuteleukemia
relapse after allogeneic hematopoietic stem cell transplanta-
tion. Of those relapses, 15% to 23% occur at extramedullary
sites without bone marrow relapse, although most patients
eventually experience bone marrow relapse within a few
months[1–3].Therelativelyhighfrequencyofisolatedextra-
medullary relapse of AML is associated with the presence of
chronic GVHD and the relapse at the later phases [3]. These
facts are consistent with the speculation that the allogeneic
immune attack is less eﬀective in the extramedullary sites
(a)
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Figure 1: (a) CT scan of the upper abdomen. Arrowheads indicate
swollen pancreas. (b) MRCP of the abdomen. Arrowheads indicate
pancreatic duct. (c) CT scan after administration of prednisolone.
than in the bone marrow [1]. Sites of extramedullary relapse
vary widely amongpatients, butthe2most commonsitesare
the central nervous system and the skin. Less common sites
include the gastrointestinal tract, breast tissue, urogenital
tract, paravertebral tissue, nasopharynx, paranasal sinus,
peritoneal cavity, and pleura [8, 9]. To our knowledge,
pancreatic swelling as a representation of AML relapse, par-
ticularly in the late phase after BMT, has not been reported.
The risk factors for extramedullary relapse based on
leukemia cell characteristics have also been reported, includ-
ing cytogenetic abnormalities such as t(8;21) and inv(16),
expression of adhesion molecules such as CD56 (NCAM),
expression of T cell markers such as CD2 and CD7, and
FAB subtypes such as M2, M4, and M5 [10, 11]. In the
present case, the leukemia cells were positive for CD56 but
negative for CD2, CD4, and CD7. The cytogenetic studyISRN Hematology 3
demonstrated t(16;21)(p11;q22) translocation as well as
other complicated abnormalities. The t(16;21)(p11;q22)
translocation results in the formation of the FUS/TLS-ERG
fusion gene [12]. Acute myeloid leukemia with this translo-
cation is known to be rare and associated with younger age
at presentation. The median age at diagnosis is 22 years.
Relapse is frequent in patients who have achieved complete
remission, suggesting that this group of patients has a poor
prognosis [13]. The FUS/TLS-ERG fusion gene consists of
an RNA-binding protein, FUS, and a transcription factor,
ERG. TLS-ERG expression alone induces a leukemogenic
program in mice [14]. Previously, we reported the case of
an AML patient with FUS/TLS-ERG who relapsed at the
left femur after allogeneic BMT [15]. Interestingly, the same
fusion gene is also detectedin Ewing sarcoma [16]. Although
an association between t(16;21)(p11;q22) translocation and
extramedullary relapse hasnotbeenreported,itisinteresting
that the patients we reported here and previously had
extramedullary relapse.
In summary, we have reported a case of a patient with
relapsed AML with t(16;21)(p11;q22) who presented with
pancreatitis as a representation of extramedullary relapse
after a second allogeneic BMT. Extramedullary relapse of
AML should be considered in the patient who presents pan-
creatitis-like signs and symptoms after BMT.
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